Corrigendum: “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)” (Annals of Oncology (2020) 31(1) (79–87), (S0923753419354055), (10.1016/j.annonc.2019.09.004))

  • M. Kundranda
  • , A. C. Gracian
  • , S. F. Zafar
  • , E. Meiri
  • , J. Bendell
  • , H. Algül
  • , F. Rivera
  • , E. R. Ahn
  • , D. Watkins
  • , U. Pelzer
  • , V. Charu
  • , A. Zalutskaya
  • , G. Kuesters
  • , J. M. Pipas
  • , S. Santillana
  • , V. Askoxylakis
  • , A. H. Ko

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Fingerprint

Dive into the research topics of 'Corrigendum: “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)” (Annals of Oncology (2020) 31(1) (79–87), (S0923753419354055), (10.1016/j.annonc.2019.09.004))'. Together they form a unique fingerprint.

Keyphrases

Agricultural and Biological Sciences

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology